Binimetinib

(Mektovi®)

Mektovi®

Drug updated on 5/17/2024

Dosage FormTablet (oral; 15 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
  • Indicated in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Binimetinib (Mektovi) is indicated in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma and non-small cell lung cancer, both specifically with a BRAF V600E or V600K mutation as detected by an FDA-approved test.
  • Nine systematic reviews/meta-analyses were reviewed to gather information about Mektovi's efficacy and safety profile.
  • The combination therapy of binimetinib and encorafenib shows a superior overall response rate compared to other double and triple therapies such as dabrafenib + trametinib, vemurafenib + cobimetinb for treating metastatic melanoma.
  • For patients suffering from metastatic colorectal cancer (mCRC) carrying BRAF V600E mutations, the addition of binimetinib to a regimen including encorafenib significantly improves patient outcomes when compared to conventional therapy.
  • Subgroup analyses suggest that younger patients (<55 years) may experience increased risk factors like pulmonary embolism and arterial hypertension due to this drug combo; hence, individual patient factors should be considered.
  • Immunotherapies like nivolumab or ipilimumab tend to have better acceptability regarding adverse events than targeted therapies such as MEK inhibitors after 12 months, indicating long-term benefits.

Product Monograph / Prescribing Information

Document TitleYearSource
Mektovi (binimetinib) Prescribing Information.2023Array BioPharma Inc., Boulder, CO

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: results from a systematic literature review and a network meta-analysis.2022Cancer Treatment Reviews
Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer.2022Critical Reviews in Oncology/Hematology
Acceptability of drugs in the treatment of unresectable/metastatic BRAF V600-mutant melanoma: a systematic review and network meta-analysis.2022Frontiers in Oncology
Comparative efficacy of dabrafenib + trametinib versus treatment options for metastatic melanoma in first-line settings.2021Journal of Comparative Effectiveness Research
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma.2021ESMO Open
Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma.2020Clinical and Translational Oncology
Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF Inhibitors: a systematic review.2019Cancers
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.2019European Journal of Cancer
Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis.2019JAMA Network

Clinical Practice Guidelines